Precision Medicine & Diagnostics
GRAIL
by GRAIL, LLC
Multi-cancer early detection blood test identifying 50+ cancers at a single annual screening
Category
Precision Medicine & Diagnostics
Founded
2016
Headquarters
Menlo Park, CA, USA
Overview
GRAIL is a healthcare company focused on early cancer detection through its Galleri blood test, which screens for more than 50 types of cancer from a single blood draw using a next-generation sequencing approach to detect methylation patterns in circulating cell-free DNA. The test is designed to complement existing single-cancer screening programs (mammography, colonoscopy, PSA) by detecting cancers for which no standard-of-care screening currently exists, including pancreatic, ovarian, and brain cancers. Galleri is available as a prescription laboratory test for adults at elevated cancer risk (age 50 and above) and is being evaluated in large-scale studies including the NHS-Galleri trial in the UK, which enrolled 140,000 participants. Early clinical data shows the test detects cancer signal across 50+ cancer types with a low false-positive rate (~0.5%), and importantly provides tissue of origin signal to guide follow-up workup. GRAIL also offers Shield for colorectal cancer early detection. GRAIL's differentiation is its whole-methylome sequencing approach and the scale of its training dataset — over 15,000 cancer and non-cancer samples with paired tissue data — which underlies Galleri's multi-cancer specificity and sensitivity. Originally a Illumina spinout, GRAIL went through a complex regulatory journey including an EU merger investigation before operating independently. The Galleri trial data suggests early-stage detection could meaningfully reduce cancer mortality through earlier intervention.
Key Features
Regulatory Submission Support
Automated documentation and evidence packages for FDA submission of diagnostic tests.
Genomic Biomarker Discovery
AI-powered analysis of clinical sequencing data identifies actionable biomarkers in hours.
Multi-Modal Patient Profiling
Integration of genomic, clinical, imaging, and real-world data for comprehensive patient profiles.
Clinical Trial Matching
Automated matching of patients to clinical trials based on genomic profiles and eligibility criteria.
Companion Diagnostic Development
AI-driven biomarker discovery and validation for companion diagnostic test development.
Pros & Cons
Pros
- +Real-world evidence platform aggregates de-identified patient data from major healthcare systems
- +Multi-modal data integration combines genomic, clinical, and imaging data for comprehensive patient profiling
- +AI-powered genomic analysis identifies actionable biomarkers from clinical sequencing data in hours
- +Longitudinal patient tracking enables outcomes-based analysis of treatment effectiveness
- +Partnerships with 50%+ of US academic medical centers provide diverse patient population coverage
- +FDA-cleared diagnostic tests validate AI-driven biomarker discoveries for clinical use
- +Companion diagnostic development accelerates clinical trial matching and treatment selection
Cons
- −Clinical validation and regulatory approval processes are lengthy and resource-intensive
- −Clinical adoption depends on physician trust in AI-generated recommendations
- −Privacy and consent requirements for patient data use add complexity and cost
- −Reimbursement pathways for AI-driven diagnostics remain uncertain in many healthcare markets
Use Cases
Genomic-Guided Treatment Selection
AI-powered analysis of patient genomic data to identify actionable biomarkers and match patients to optimal therapies.
Clinical Trial Matching
Automated matching of patients to clinical trials based on genomic profile, medical history, and trial eligibility criteria.
Real-World Evidence Generation
Aggregation and analysis of de-identified patient data from healthcare systems to generate real-world evidence.